FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2119261750> ?p ?o ?g. }

• W2119261750 endingPage "216" @default.
• W2119261750 startingPage "206" @default.
• W2119261750 abstract "The fluid filling renal cysts in human polycystic kidneys is secreted chiefly by the tubular epithelium lining the cysts via secondary chloride transport. Inhibiting this process by somatostatin therapy should induce shrinking of renal cysts.In this randomized, cross-over, placebo-controlled trial we compared the risk/benefit profile of 6-month treatment with long-acting somatostatin (octreotide-LAR, 40 mg intramuscularly every 28 days) or placebo in autosomal-dominant polycystic kidney disease (ADPKD) patients with mild-to-moderate renal insufficiency and no evidence of other kidney disease. Volumes of kidney structures were evaluated by a two-slice computed tomography (CT) scanner; while glomerular filtration rate (GFR) was estimated by iohexol plasma clearance.One patient on somatostatin and one on placebo were prematurely withdrawn because of nonsymptomatic, reversible colelithiasis and asthenia, respectively. In the remaining 12 patients somatostatin was well tolerated. Kidney volume increased by 71 +/- 107 mL (P < 0.05) on somatostatin and by 162 +/- 114 mL (P < 0.01) on placebo. The percent increase was significantly lower on somatostatin (2.2 +/- 3.7% vs. 5.9 +/- 5.4%) (P < 0.05). Cystic volume tended to increase less on somatostatin than on placebo (3.0 +/- 6.5% vs. 5.6 +/- 5.8%). The parenchymal volume nonsignificantly increased by 2.5 +/- 8.4% on placebo and slightly decreased by 4.4 +/- 8.9% on somatostatin. The GFR did not change significantly during both treatment periods.In ADPKD patients, 6-month somatostatin therapy is safe and may slow renal volume expansion. This may reflect an inhibited growth in particular of smallest cysts beyond the detection threshold of CT scan evaluation. Whether this effect may prove renoprotective in the long term should be tested in additional trials of longer duration." @default.
• W2119261750 created "2016-06-24" @default.
• W2119261750 creator A5002765637 @default.
• W2119261750 creator A5027726576 @default.
• W2119261750 creator A5029489154 @default.
• W2119261750 creator A5036777432 @default.
• W2119261750 creator A5050920108 @default.
• W2119261750 creator A5059276594 @default.
• W2119261750 creator A5063980981 @default.
• W2119261750 creator A5076316519 @default.
• W2119261750 date "2005-07-01" @default.
• W2119261750 modified "2023-09-27" @default.
• W2119261750 title "Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease" @default.
• W2119261750 cites W1505552009 @default.
• W2119261750 cites W1922782512 @default.
• W2119261750 cites W1972108304 @default.
• W2119261750 cites W1976362363 @default.
• W2119261750 cites W1987353631 @default.
• W2119261750 cites W1988192546 @default.
• W2119261750 cites W1990640296 @default.
• W2119261750 cites W1992093075 @default.
• W2119261750 cites W1992375867 @default.
• W2119261750 cites W1993430549 @default.
• W2119261750 cites W1996678974 @default.
• W2119261750 cites W2000249634 @default.
• W2119261750 cites W2008743566 @default.
• W2119261750 cites W2013620388 @default.
• W2119261750 cites W2022985790 @default.
• W2119261750 cites W2028464499 @default.
• W2119261750 cites W2033196626 @default.
• W2119261750 cites W2041546338 @default.
• W2119261750 cites W2043524463 @default.
• W2119261750 cites W2058437996 @default.
• W2119261750 cites W2063092306 @default.
• W2119261750 cites W2132018948 @default.
• W2119261750 cites W2136871445 @default.
• W2119261750 cites W2146041633 @default.
• W2119261750 cites W2167412004 @default.
• W2119261750 cites W2170402320 @default.
• W2119261750 cites W2410336182 @default.
• W2119261750 cites W3021964512 @default.
• W2119261750 cites W4239520211 @default.
• W2119261750 cites W4250058955 @default.
• W2119261750 cites W4255304452 @default.
• W2119261750 doi "https://doi.org/10.1111/j.1523-1755.2005.00395.x" @default.
• W2119261750 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15954910" @default.
• W2119261750 hasPublicationYear "2005" @default.
• W2119261750 type Work @default.
• W2119261750 sameAs 2119261750 @default.
• W2119261750 citedByCount "239" @default.
• W2119261750 countsByYear W21192617502012 @default.
• W2119261750 countsByYear W21192617502013 @default.
• W2119261750 countsByYear W21192617502014 @default.
• W2119261750 countsByYear W21192617502015 @default.
• W2119261750 countsByYear W21192617502016 @default.
• W2119261750 countsByYear W21192617502017 @default.
• W2119261750 countsByYear W21192617502018 @default.
• W2119261750 countsByYear W21192617502019 @default.
• W2119261750 countsByYear W21192617502020 @default.
• W2119261750 countsByYear W21192617502021 @default.
• W2119261750 countsByYear W21192617502022 @default.
• W2119261750 countsByYear W21192617502023 @default.
• W2119261750 crossrefType "journal-article" @default.
• W2119261750 hasAuthorship W2119261750A5002765637 @default.
• W2119261750 hasAuthorship W2119261750A5027726576 @default.
• W2119261750 hasAuthorship W2119261750A5029489154 @default.
• W2119261750 hasAuthorship W2119261750A5036777432 @default.
• W2119261750 hasAuthorship W2119261750A5050920108 @default.
• W2119261750 hasAuthorship W2119261750A5059276594 @default.
• W2119261750 hasAuthorship W2119261750A5063980981 @default.
• W2119261750 hasAuthorship W2119261750A5076316519 @default.
• W2119261750 hasBestOaLocation W21192617501 @default.
• W2119261750 hasConcept C126322002 @default.
• W2119261750 hasConcept C126894567 @default.
• W2119261750 hasConcept C134018914 @default.
• W2119261750 hasConcept C142724271 @default.
• W2119261750 hasConcept C159641895 @default.
• W2119261750 hasConcept C204787440 @default.
• W2119261750 hasConcept C27081682 @default.
• W2119261750 hasConcept C2776266639 @default.
• W2119261750 hasConcept C2776297358 @default.
• W2119261750 hasConcept C2778653478 @default.
• W2119261750 hasConcept C2780091579 @default.
• W2119261750 hasConcept C2780145431 @default.
• W2119261750 hasConcept C71924100 @default.
• W2119261750 hasConcept C90924648 @default.
• W2119261750 hasConceptScore W2119261750C126322002 @default.
• W2119261750 hasConceptScore W2119261750C126894567 @default.
• W2119261750 hasConceptScore W2119261750C134018914 @default.
• W2119261750 hasConceptScore W2119261750C142724271 @default.
• W2119261750 hasConceptScore W2119261750C159641895 @default.
• W2119261750 hasConceptScore W2119261750C204787440 @default.
• W2119261750 hasConceptScore W2119261750C27081682 @default.
• W2119261750 hasConceptScore W2119261750C2776266639 @default.
• W2119261750 hasConceptScore W2119261750C2776297358 @default.
• W2119261750 hasConceptScore W2119261750C2778653478 @default.
• W2119261750 hasConceptScore W2119261750C2780091579 @default.
• W2119261750 hasConceptScore W2119261750C2780145431 @default.

• next